AFYA Stock - Afya Limited
Unlock GoAI Insights for AFYA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.30B | $2.88B | $2.33B | $1.72B | $1.20B |
| Gross Profit | $2.09B | $1.77B | $1.47B | $1.07B | $766.54M |
| Gross Margin | 63.2% | 61.4% | 63.1% | 62.1% | 63.8% |
| Operating Income | $1.01B | $767.06M | $664.10M | $440.89M | $363.33M |
| Net Income | $631.51M | $386.32M | $373.57M | $223.33M | $292.07M |
| Net Margin | 19.1% | 13.4% | 16.0% | 13.0% | 24.3% |
| EPS | $7.01 | $4.27 | $4.15 | $2.39 | $3.15 |
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. The company also provides digital health services, such as subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides medical postgraduate specialization programs; printed and digital content; and an online medical education platform and practical medical training services. As of December 31, 2021, it operated a network of 46 undergraduate and graduate medical school campuses consisted of 30 undergrad operating units and five approved units; and a network of 2,731 medical school seats that consisted of 2,481 operating seats and 278 approved seats. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 8th 2025 | JP Morgan | Upgrade | Overweight | $24.5 |
| September 8th 2025 | UBS | Upgrade | Buy | $19 |
| August 6th 2025 | Morgan Stanley | Upgrade | Overweight | $17.5 |
| July 29th 2025 | Citigroup | Upgrade | Neutral | $14 |
| March 11th 2025 | Morgan Stanley | Downgrade | Underweight | $17← $19 |
| January 31st 2025 | Citigroup | Downgrade | Sell | $15← $18 |
| December 3rd 2024 | Goldman | Initiation | Sell | $16 |
| August 30th 2024 | UBS | Initiation | Neutral | $19.5 |
| January 29th 2024 | Citigroup | Initiation | Neutral | $23 |
| January 22nd 2024 | Morgan Stanley | Downgrade | Equal Weight | $23← $20.5 |
| October 13th 2023 | Morgan Stanley | Upgrade | Overweight | $20.5← $16.5 |
| April 8th 2022 | Credit Suisse | Upgrade | Outperform | $19← $18 |
Earnings History & Surprises
AFYAEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $0.40 | — | — | — |
Q4 2025 | Nov 12, 2025 | $0.32 | $0.38 | +18.8% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $0.40 | $0.40 | 0.0% | = MET |
Q2 2025 | May 8, 2025 | $0.46 | $0.55 | +19.6% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $0.34 | $0.36 | +5.9% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $0.36 | $0.32 | -11.1% | ✗ MISS |
Q3 2024 | Aug 15, 2024 | $0.37 | $0.44 | +18.9% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $0.47 | $0.55 | +17.0% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $0.34 | $0.36 | +5.9% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $0.31 | $0.28 | -9.7% | ✗ MISS |
Q3 2023 | Aug 28, 2023 | $0.33 | $0.29 | -12.1% | ✗ MISS |
Q2 2023 | May 24, 2023 | $0.39 | $0.34 | -12.8% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $0.31 | $0.26 | -16.1% | ✗ MISS |
Q4 2022 | Nov 21, 2022 | $0.26 | $0.24 | -7.7% | ✗ MISS |
Q3 2022 | Aug 22, 2022 | $0.23 | $0.26 | +13.0% | ✓ BEAT |
Q2 2022 | May 23, 2022 | $0.30 | $0.34 | +13.3% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $0.16 | $0.19 | +18.8% | ✓ BEAT |
Q4 2021 | Nov 22, 2021 | $0.17 | $0.11 | -35.3% | ✗ MISS |
Q3 2021 | Aug 26, 2021 | $0.20 | $0.03 | -85.0% | ✗ MISS |
Latest News
Afya Affirms FY2025 Sales Guidance of $626.675M-$643.750M
📈 PositiveAfya Q3 Adj. EPS $0.38 Beats $0.31 Estimate, Sales $170.420M Beat $168.750M Estimate
📈 PositiveAfya Limited Announces That Brazil's Ministry Of Education Has Approved The Addition Of 100 Medical School Seats At ITPAC Porto Nacional
📈 PositiveAFYA stock has given up its prior gain. Afya shares were trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $23.5 to $24.5.
➖ NeutralAfya shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $23.5 to $24.5. Also, UBS upgraded the stock from Neutral to Buy.
📈 PositiveUBS Upgrades Afya to Buy, Lowers Price Target to $19
📈 PositiveJP Morgan Upgrades Afya to Overweight, Raises Price Target to $24.5
📈 PositiveFrequently Asked Questions about AFYA
What is AFYA's current stock price?
What is the analyst price target for AFYA?
What sector is Afya Limited in?
What is AFYA's market cap?
Does AFYA pay dividends?
Similar Stocks
Consumer Defensive SectorExplore stocks similar to AFYA for comparison